Compartmentalization of cAMP and PKA activity in cardiac muscle cells plays a key role in maintaining basal and enhanced contractility stimulated by sympathetic nerve activity. In cardiomyocytes, activation of adrenergic receptor increases cAMP production, which is countered by the hydrolytic activity of selective phosphodiesterases (PDEs). The intracellular regional dynamics of cAMP production and hydrolysis modulate downstream signals resulting in different biological responses. The interplay between beta receptors (bARs) signalling and phosphodiesterase 5 (PDE5) activity remains to be addressed.
Introduction
The beta adrenoceptors (bARs) belong to the family of G-proteincoupled heptahelical receptors and control a wide range of processes in cardiac pathophysiology. 1, 2 Stimulation of bARs activates a complex downstream signalling that differs according to cell type, stage of development, receptor desensitisation, partner molecules, cofactors, and second messenger targets. 3 Isolated neonatal cardiomyocytes express all three bAR subtypes. 4 b 1 AR stimulation is significantly more efficient than b 2 AR at increasing sarcomeric shortening, probably due to its predominant activation of the classic Gs-cAMP pathway, while b 2 AR sequentially activates both the Gs and Gi pathways. 5 In contrast, b 3 AR stimulation has a negative inotropic effect through the elevation of intracellular cGMP concentration. 6, 7 This oversimplified view is made much more complex by a number of co-factors and variables that modulate bAR signalling. 3 Subtype-specific regulation of bAR signalling might, for example, occur through differential cAMP degradation, which is under the control of the phosphodiesterase (PDE) multigenic superfamily. 8, 9 Among the 11 PDE families thus far identified, at least five are expressed in the heart: the Ca 2+ calmodulin-dependent PDE1 family; the PDE2 family comprising dual-nucleotide specific esterase activity stimulated by cGMP; the cGMP-inhibited cAMP-specific PDE3 family; the cAMP-specific PDE4; and the cGMP-specific PDE5. 10, 11 Although PDE3 and PDE4 provide the main esterase activity in rodent hearts, 6, 12 several studies suggest that PDE2 may also control important biological functions by hydrolysing both cAMP and cGMP. 13 -15 There is growing evidence that PDE5 protein is expressed in cardiomyocytes and up-regulated in several pathological conditions 16 -18 via an oxidant stress-dependent mechanism. 19 Pharmacological inhibition of PDE5 with sildenafil, a powerful selective inhibitor, has proved effective in counteracting cardiac hypertrophy in animal models. 20 Encouraging data are also emerging from clinical trials in heart failure. 21 We recently demonstrated that sildenafil exerts anti-remodelling effects in diabetic cardiomyopathy, 22 while others have investigated its effects postischaemia. 23 However, the molecular mechanisms of sildenafil action on cardiac homeostasis are still under investigation. It is known that sildenafil occupy the catalytic site as pseudo substrates, blocking esterase activity and leading to increased cGMP levels. The rise in intramyocyte cGMP subsequently modulates the activation of PKG. 11 The negative inotropic effect of PDE5 inhibitors after b-adrenergic stimulation has also been reported in several species, 7, 24 including humans. 25 However, its effects on contraction frequency have not been previously addressed because of the intrinsic limitations of the investigated models.
To examine the contribution of PDE5A inhibition to b 1 AR-, b 2 AR-, and b 3 AR-stimulated contraction rate, we took advantage of an in vitro beating assay performed on cultured neonatal cardiomyocytes 4 and measured the cardiac rate under different conditions. In contrast to adults, neonatal ventriculocytes maintain their plasticity, allowing them to form spontaneous beating syncytia and to respond to b-adrenergic stimuli. Using a combined pharmacological and genetic approach based on selective disruption of the activities and genes encoding different bARs and PDEs, we provide an insight into the integrated response to adrenergic stimulation via a PDE5 -cGMP-PDE2 cascade that works regionally to inhibit b 2 AR signalling in neonatal ventriculocytes.
Methods
Detailed methods are described in the Supplementary material online. 
Mice generation
b 1 AR 2/2 , b 2 AR 2/2 ,
RT-PCR
cDNAs were tested for the expression of different Pde isoforms in the heart and cardiomyocytes and for Pde2 in MEF and cardiomyocytes isolated from Pde2 +/+ , Pde2 2/2 , Pde2 +/2 (mPDE2F, mPDE2R) using the primer pairs listed in Supplementary material online, Table S1 .
Statistical analyses
Data are presented as rate increase over basal level + SE. One-way or two-way ANOVA was used for statistical analyses. P-values ,0.05 were considered significant. Unless otherwise indicated, significance refers to isoproterenol (Iso) stimulation. PDE5 modulates contraction rate through PDE2 the ventricular wall in vivo ( Figure 1 ). mRNAs from embryonic (9 dpc), fetal (17 dpc), neonatal (1-2 dpp), and adult (3 months) mouse hearts were extracted and RT-PCRs were performed to evaluate the expression of PDE isoforms. PDE1A, 1C, 2A, 3A and B, 4A, B and D, 5A, 7A, 8A and 9 mRNAs are expressed with a similar pattern in the intact ventricular wall and in isolated cultured cardiomyocytes ( Figure 1A and B). To confirm at protein level the PDE expression detected by RT-PCR, immunoprecipitation and western blotting analyses were performed on lysates from neonatal hearts and freshly isolated cardiomyocytes. Figure 1C and Supplementary material online, Figure S1A confirmed that PDE1C, PDE2A, PDE3A, and PDE5A proteins are expressed in mouse hearts ( Figure 1C left panel) and isolated cardiomyocytes in culture ( Figure 1C right panel and Supplementary material online, Figure S1A ). These data confirm that cardiomyocyte syncytia are a suitable cellular model to investigate the effects of cyclic nucleotide fluctuation through modulation of PDE activities.
Results

PDE expression in neonatal mouse hearts and cultured cardiomyocytes
PDE5 modulates bAR-stimulated contraction rate in cardiomyocyte syncytia
In mouse neonatal cardiomyocytes, bAR stimulation produces a strong acceleration of the spontaneous contraction rate (Figure 2) . In wild-type myocytes, treatment with 1 mmol/L sildenafil has no effect on the spontaneous contraction rate compared with untreated cells (Figure 2A) , although a moderate reduction was observed in the late phase of the beating assay ( Figure 2A , P , 0.05). In contrast, pre-treatment with 1 mmol/L of sildenafil strongly counteracted the increased contraction rate stimulated by 10 mmol/L of b-agonist Iso (Figure 2A ). The peak of contraction rate was not significantly reduced compared with Isostimulated samples, but the effect of sildenafil becomes statistically detectable as early as 9 min after Iso addition. The subsequent sustained phase (10 -30 min) was strongly affected by the presence of sildenafil, with a normalization to the pre-stimulation contraction rate within 25 min after Iso ( Figure 2A ). Sildenafil pre-conditioning (1 mmol/L) almost doubled intracellular cGMP levels measured by FRET analysis after Iso stimulation, marginally affecting unstimulated levels ( Figure 2B ). These results indicate that sildenafil/cGMP has a minimal impact on the peak response to Iso while strongly affecting the sustained phase of bAR response. Since high-dose sildenafil can inhibit the PDE1C isoform as well as PDE5, 33 we performed a dose-response curve to test the lowest concentration of sildenafil able to blunt the effect of a saturating dose of Iso on contraction rate. Figure 2C shows that as little as 1-10 nmol/L of sildenafil-below the EC 50 for PDE1C 33 -retains an inhibitory effect on 10 mmol/L Iso stimulation. Dose-response curves for Iso and sildenafil revealed that as little as 10 nmol/L sildenafil is capable of inhibiting the frequency response after a non-saturating dose of Iso (Supplementary material online, Figure S1B ). Similar data were obtained using 0.5 mmol/L tadalafil, another selective PDE5 inhibitor with a longer half-life and a different catabolism (data not shown), further suggesting that PDE5 plays a central role in the modulation of bAR response in spontaneously beating cardiomyocytes.
PDE5 inhibition of b-adrenergic chronotropic effect requires an intact PDE2 activity
To explore the role of PDEs in cardiomyocytes beat modulation, we recorded the spontaneous and bAR-stimulated contraction rate of neonatal cardiomyocytes assayed in the presence of specific PDE2 and PDE3 inhibitors, with or without sildenafil pre-conditioning. The PDE3-specific inhibitor cilostamide per se did not affect or bARstimulated contraction rate (Supplementary material online, Figure S2A and C), as previously reported. 6, 34 However, combined pre-treatment with sildenafil and cilostamide produced a statistically significant reduction in both the peak (5-9 min) and the sustained (10-30 min) bARstimulated contraction rate compared with non-pre-conditioned cardiomyocytes ( Figure 3A) . Specifically, there was a 64 + 9% of reduction in b-adrenergic contraction peak followed by a gradual decline to the basal contraction rate. The synergistic effect obtained by the combination of these two inhibitors suggests that PDE5 and PDE3 are components of two distinct pathways that independently regulate cardiac contraction rate. These results were extended and confirmed by cAMP and cGMP FRET analyses (Supplementary material online, Figure S3A and B).
Cilostamide has no additional effect on the cGMP increase induced by Iso and sildenafil (Supplementary material online, Figure S3B ), but further reduces cAMP levels after Iso and sildenafil conditioning (Supplementary material online, Figure S3A ). The administration of erythro-9-(2-hydroxy-3-nonly)adenine hydrochloride (EHNA), a specific PDE2 inhibitor, had no effect on the contraction rate of un-stimulated cardiomyocytes (Supplementary material online, Figure S2B ). Similarly, EHNA had no effect on Iso-stimulated frequency (Supplementary material online, Figure S2D ). However, when combined with sildenafil, EHNA abolished sildenafil's effect during the sustained phase after Iso stimulation (10-30 min) ( Figure 3B ). Contraction rate is coupled to cytoplasmic calcium release. As shown in Figure 3C , sildenafil pre-treatment blunted Iso-induced calcium mobilization in neonatal cardiomyocytes, while EHNA restored calcium transients, replicating the beating cells results. Heart contraction rate is regulated by the SAN, in which pacemaker is placed. Isolated SAN region was treated with the same drug protocols as neonatal cardiomyocytes: Iso doubled the spontaneous The data represent mean + SE of at least five experiments performed in different myocyte preparations; two-way ANOVA showed a significant difference in time course: *P , 0.05,**P , 0.01, and ***P , 0.001. (D and E) PDE5 inhibition decreases the contraction rate induced by 10 mmol/L Iso in Pde2
but not in Pde2 +/2 (E) neonatal cardiomyocytes. The data represent mean + SE of at least 10 experiments performed in different myocyte preparations;
two-way ANOVA showed a significant difference in time course: *P , 0.05, **P , 0.01, and ***P , 0.001. (F) Immunofluorescence of PDE5A (red) and PDE2A (green) in isolated neonatal cardiomyocytes. Arrowheads indicate PDE co-localization in the plasma membrane. Scale bar 20 mm.
PDE5 modulates contraction rate through PDE2
node beating frequency and sildenafil completely counteracted this effect, while EHNA significantly reversed sildenafil's effect on the SAN beating rate ( Figure 3D and E) . Taken together, these data indicate that PDE2 is activated consequent to PDE5 inhibition and that it is necessary for sildenafil attenuation of b-adrenergic signalling.
PDE2 haploinsufficiency prevents PDE5 inhibition effect in embryonic and neonatal cardiomyocytes
In order to prove the centrality of PDE2 the b-blocking effects of sildenafil, we used gene-targeted mouse lines, Pde2 2/2 mice, in which phosphodiesterase expression had been switched off (Supplementary material online, Figure S4A and B). 35 To study the effect of the complete absence of Pde2 expression on beating assays, we established Pde2 +/+ , Pde2 +/2 , and Pde2 2/2 cell cultures from the hearts of E14.5 -15.5 dpc embryos, due to the high lethality of this mouse line after E17.5 -E18.5 dpc (EMMA website and Table 1) . 35 As observed with wild-type neonatal cultures, sildenafil pre-treatment reduced the bAR-stimulated contraction rate in Pde2 +/+ embryonic cardiomyocytes ( Figure 4A ).
In contrast, the bAR-stimulated contraction frequency of cardiomyocytes lacking one or both Pde2 alleles was minimally or not at all affected by sildenafil [respectively 7 and 0% for Pde2 +/2 and Pde2
2/2
( Figures 4B and C) ]. RT-PCR and western blotting analyses excluded that this event was due to modified PDE5 expression in Pde2 +/2 and Pde2 2/2 compared with Pde2 +/+ embryonic cardiomyocytes (Supplementary material online, Figure S4A and B). Similar results were obtained using neonatal Pde2 +/2 cardiomyocyte cultures compared with
Pde2
+/+ cells ( Figure 4D and E) . Furthermore, immunofluorescence analyses revealed co-localization of PDE5 and PDE2 (7.3 + 1.44% of co-localization area), but not PDE3 in the plasma membrane ( Figure 4F and Supplementary material online, Figure S5 ), suggesting a possible interaction between PDE2 and PDE5. In summary, Pde2 haploinsufficiency prevents sildenafil attenuation of Iso-stimulated beating, confirming that PDE2 is involved in the regulation of the b-adrenergic response and that PDE5 inhibition could be a new modulator of PDE2 activity.
3.5 bAR-specific c-AMP pool is modulated by sildenafil FRETcAMP-ICUE3 biosensor was then used to measure cAMP fluctuations in response to Iso, sildenafil, and EHNA. As shown in Figure 5A and Supplementary material online, Figure S3A , sildenafil treatment significantly reduced cAMP response after Iso stimulation in neonatal cardiomyocytes. However, we demonstrated that PDE5-dependent modulation of cAMP is prevented by EHNA, in keeping with the hypothesis that cAMP reduction occurs through PDE2 activation.
To demonstrate that the observed effects of PDE5 inhibition were specific to b-adrenergic-cAMP stimulation, we used non-receptorial activation of cAMP by forskolin. In fact, there were no significant effects of sildenafil on forskolin-dependent stimulation of cardiomyocyte contraction rate ( Figure 5B) or cAMP and cGMP levels (Supplementary material online, Figure S6A and B).
Given the possible coupling of the b 2 AR with Gi, we pre-treated cells with pertussis toxin to inactivate the inhibitory G proteins. Inactivation of Gi did not alter the b 2 AR-mediated contraction rate after sildenafil ( Figure 5C ), indicating similar Gs-dependent cAMP production and reinforcing the theory that the observed effects were mediated by enhanced cAMP hydrolysis rather than by reduced cAMP generation.
Taken together, these results support the hypothesis that PDE2 is a target of the cGMP -PDE5 pathway for the regulation of the sustained phase of b-adrenergic response. In addition, PDE3 phosphodiesterase activity was found to be independent of PDE5 activity in the sustained phase. Both PDE3 and PDE5 activity act together in controlling the early phase of beating rate after bAR stimulation, as revealed by the combined inhibitions.
PKG inhibition affects spontaneous and b-adrenergic-stimulated beating rate
To test whether protein kinase G plays a part in the modulation of neonatal cardiomyocyte beating after Iso stimulation, we used DT2, a specific peptide blocker of PKG. The effect of DT2 treatment was first assessed in untreated cells and it was noted that PKG inhibition significantly affected the spontaneous contraction rate, leading to a gradual but substantial slowing of the contraction rate over the assay ( Figure 6A ). The effects of DT2 were partially antagonized when the inhibitor was PDE5 modulates contraction rate through PDE2 used in combination with sildenafil ( Figure 6A , DT2+sildenafil vs. DT2, P , 0.05 for each time point). In DT2-treated cardiomyocytes, there was almost no response to bAR stimulation ( Figure 6B ) and simultaneous addition of sildenafil did not produce any significant change (Iso+ sildenafil+DT2 vs. Iso+sildenafil, P . 0.05 for each time point, Figure 6C ). Experiments were repeated using 1 and 100 nmol/L DT2 ( Figure 6D) . A DT2 dose-dependent decrease in contraction rate was observed after Iso stimulation and no dose of DT2 was able to reverse the negative chronotropic effect of sildenafil, which on the contrary seemed to be potentiated by DT2 co-treatment. These results indicate that PKG directly influences ventricular beating frequency under basal or Iso-stimulated conditions and is probably not directly involved in the molecular mechanisms elicited by PDE5 inhibition of contraction rate.
3.7 Selective bAR signalling is regulated by PDE5 activity b 1 AR and b 2 AR stimulations, acting through different pools of cAMP, elicits distinct effects on cardiomyocyte contraction rate. 4, 6 We therefore analysed the role of PDE5 in bAR subtype-mediated signalling in cardiomyocytes isolated from b 1 AR 2/2 , b 2 AR 2/2 , and double
In the absence of the b 1 receptor, the peak of contraction after Iso stimulation was significantly reduced compared with the peak of wild-type cardiomyocytes ( Figure 7A ). Sildenafil significantly attenuated the b 2 AR-mediated response during the Iso-sustained phase of the beating assay ( Figure 7A ), but had no effect on the stimulation mediated by b 1 AR in b 2 AR 2/2 or b 3 AR in b 1 b 2 AR 2/2 myocytes ( Figure 7B and C) . Similar results were obtained by selective (Figure 7D and E) . These experiments clearly suggest that PDE5 inhibition affects b 2 but not b 1 signalling.
To understand if PDE2 mediates the effect of PDE5 inhibition on b 2 AR stimulation, cells were pre-treated with sildenafil plus EHNA. Treatment with PDE2 inhibitor reversed the b-blocking effect of sildenafil in b 1 AR 2/2 but not in b 2 AR 2/2 cardiomyocytes ( Figure 7A and B).
To rule out the possibility that the observed effects on b 2 AR signalling by sildenafil were caused by altered PDE5 expression in bAR 2/2 cardiomyocytes, PDE5 mRNA and protein levels were measured in b 1 AR 2/2 , as well as in b 2 AR 2/2 , b 1 b 2 AR 2/2 , and wild-type hearts. The total PDE5 amount was comparable in hearts obtained from mice with the different genotypes (Supplementary material online, Figure S4C ). Taken together, these results suggest that PDE5 selectively modulates the b 2 -dependent signalling cascade activated by adrenergic stimuli.
Discussion
In this study, we identify the effects of PDE5 inhibition on the b-adrenergic signalling on contraction frequency and a receptor-specific interplay between cGMP and cAMP through different PDE activities.
PDE5 inhibition decreases b-adrenergic-dependent contraction rate
All three bAR subtypes are expressed in neonatal cardiomyocytes and each bAR subtype, coupling to distinct signalling pathways, influences the spontaneous beating rate of cardiomyocytes in culture. 4 The specific functions of these subtypes have not been completely established and neonates may differ from adults in terms of localization, desensitization, and intensity of cAMP generation. 36 Nevertheless, the unique feature of spontaneous beating of neonatal cardiomyocytes offers a valuable ex-vivo model to investigate chronotropism. Studies in dogs, rats, and mice have demonstrated that PDE5 regulates bAR cardiac response. 37, 38 However, in vivo experiments do not allow investigation of whether sildenafil functions through systemic vasculature or directly on cardiomyocytes. 39 Consistently with previous studies, 4, 6, 40 we found a potent, dose-dependent chronotropic effect of Iso in isolated neonatal cardiomyocytes ( Figure 2A and Supplementary material online, Figure S1B ). When PDE5 was inhibited with sildenafil, cGMP levels increased ( Figure 2B ) and the bAR-stimulated contraction rate was significantly lowered (Figure 2A ). This result points to a novel role for cGMP in attenuating beta-adrenergic response. Sildenafil alone induced very low cGMP accumulation, with negligible effects on basal cardiomyocytes beating, probably due to the low concentrations of the specific cAMP pool at rest. Previous and current data indicate that sildenafil acts directly on cardiomyocytes to control depolarization and contraction through different and compartmentalized pathways. 38, 41, 42 The molecular mechanisms involved are still poorly understood and for this reason, we tested whether PDE5 inhibition could modulate bAR-responsiveness by affecting PDE2, PDE3, and PKG-specific activities.
PDE2 activity is required for sildenafil inhibition of b-adrenergic response
Among the cAMP-hydrolysing PDEs expressed in the heart, PDE2 is unique, because it can be activated by rising concentrations of cGMP. 13 ,15, 43 Zaccolo and Movsesian 44 proposed the presence of crosstalk between cGMP and cAMP signalling, with PDE2 responsible for the rapid transient attenuation of adrenergic response, mainly through NO/ cGMP-dependent pathways. Recently, a pivotal role for PDE2 was demonstrated in human failing heart. 15 To address the role of PDE2, we used the PDE2 inhibitor EHNA, knockout, and haploinsufficiency mouse models. Experiments using selective inhibitor showed that PDE2 blockage reverses the negative chronotropic effects of sildenafil after Iso stimulation ( Figure 3B ). Moreover, this result was reproduced in SAN tissue isolated from right atria of adult mice. These results document that a cross-talk between PDE2 and PDE5 operates both in neonatal ventriculocytes and adult pacemaker tissue, strengthening the physiological relevance of these findings. These data are consistent a meta-analysis showing that PDE5 inhibitors lowered heart rate in subjects with right heart disease. 45 The effect of bARs stimulation on contraction rate is reflected by cAMP increase. The capacity of EHNA to abolish the effects of sildenafil can be explained by enhanced PDE2 activity, due to cGMP increase, which hydrolyses cAMP generated after Iso stimulation ( Figure 5A ). PDE2 activity seems selectively linked to receptor stimulation, as it is ineffective in blocking the intracellular rise of cAMP induced by forskolin, a drug that activates adenylate cyclase in a receptor-independent manner. 13 Our data confirm and expand this concept by showing that generalized cAMP enhancement by forskolin cannot be modulated by a cGMP-dependent activation of PDE2.
To gain insights into the downstream mechanisms of PDE5-PDE2 signalling, we measured calcium transients. PDE5 inhibition caused a decrease of the frequency in Iso-induced calcium transients which was recovered after EHNA addition ( Figure 3C ). These results fully confirm what was obtained measuring the contraction rate of cardiomyocytes.
The role of PDE2 was further confirmed by experiments conducted in beating syncytia obtained from wild-type, heterozygous, and knockout mice. Due to the high embryonic lethality of Pde2 2/2 mice ( Table 1   and 35 ), the experiments were performed using cardiomyocytes from 14.5 to 15.5 dpc embryos, which respond to Iso stimulation. 46 Sildenafil was not able to counteract Iso stimulation in Pde2 deficient embryonic cardiomyocytes ( Figure 4B and C ) , showing that PDE2 activity is required for PDE5 modulation of bAR response. Furthermore, the absence of a functional allele in neonatal cardiomyocytes is sufficient to impair sildenafil effect on the stimulated contraction rate ( Figure 4E) . The latter observation is clinically relevant since several PDE2 inhibitors are now available to therapeutically target cAMP signalling in failing hearts.
Regarding a possible role of PDE3, a known regulator of basal myocardial contractility, 47, 48 a selective inhibitor cilostamide decreased the contraction rate after Iso treatment even though not significantly (Supplementary material online, Figure S2C ), and induced a slight decrease of cAMP levels (cilo+iso vs. Iso, *P , 0.05; Supplementary material online, Figure S3A ). The effects on cAMP levels after Iso addition were further enhanced when cilostamide was used in combination with sildenafil and corresponded to the blunting of bAR stimulation, mainly in the first phase of contraction rate (Supplementary material online, Figure S3A and Figure 3A) . The possible role of PDE3 in the effects of PDE5 inhibition on contraction rate might be due to small, local cGMP increase in PDE3-and PDE5-dependent compartments after Iso stimulation (Supplementary material online, Figure S3B ). 47, 49 It is possible that the cGMP increase, due to the concomitant PDE3 and PDE5 inhibition, leads to the activation of cAMP degrading PDEs which have a major impact on the global cAMP intracellular level as shown in Supplementary material online, Figure S3A . However, further experiments are warranted to address this hypothesis.
PKG inhibition impairs contraction rate
Given that the PKG-specific peptide blocker DT2 prevents sildenafil modulation of cardiac inotropy, 7 we tested PKG inhibition effects on chronotropism in neonatal syncytia. We found that DT2 treatment itself lowered the contraction rate compared with untreated or Isotreated samples ( Figure 6A ). It is possible that in the absence of active PKG, PDE5 might not be activated via phosphorylation in Ser 92, resulting in higher level of cGMP. 50 Previous studies showed that PKG activation and subsequent troponin I phosphorylation are necessary for sarcomeric shortening, independently of PDE2 and PDE3 activity. 7 In neonatal rat cardiomyocytes, instead, inotropy has been related to PDE2 and PDE3 pathway activation. 14 In our experimental settings, DT2 did not revert the negative chronotropic effect of sildenafil on Iso stimulation, but, on the contrary, PKG inhibition synergized with PDE5 inhibition, suggesting independent pathways ( Figure 6C and D) . Similar results have also been reported on rabbit atrial cells, where inhibition of PKG by KT-5823 decreased the efficacy of Iso stimulation on cardiac L-type calcium current (I Ca ). 51, 52 Another possible mechanism through which cGMP might control chronotropism is by affecting the hyperpolarization-activated I f -like current, that is sensitive to bAR stimulation and can be detected in ventricular cardiomyocytes from hypertensive rats 53 and failing human hearts. 54 Cerbai demonstrated that I f current is enhanced by intracellular cGMP and cAMP levels, independently of phosphorylation by PKG or coupling with Gi-proteins. 55 Interestingly, Casadei and co-workers 56 showed that NO does not impede the cAMP-mediated increase in I f currents in adult ventriculocytes from hypertensive rats, suggesting that this may contribute to the enhanced arrhythmogenic effect of bAR stimulation of these animals. Further studies are warranted to investigate whether sildenafil affects I f currents of ventriculocytes. Our results do not exclude the involvement of PKG in sildenafildependent effect on contraction rate and highlight a possible contribution of PKG on basal and Iso-stimulated contraction rate.
PDE5 inhibition induces degradation of b2-dependent cAMP pool
Given the ascertained existence of subcellular compartmentalized pools of cAMP, 6, 14, 57, 58 we hypothesized that sildenafil might selectively affect cAMP pools deriving from the activation of specific b-receptor subtypes.
FRET-based studies in neonatal cardiomyocytes first revealed that cAMP stimulated by b-adrenergic agonists appears in microdomains near T-tubules/junctional sarcoplasmic reticulum, and its diffusion is markedly limited by localized PDEs. 59 Whereas b 1 AR stimulation produces a significant cAMP elevation that is uniformly propagated throughout the cardiomyocyte, b 2 AR stimulation leads to a much smaller increase in cAMP that remains confined to subcellular compartments. Previous studies attribute early chronotropic effects to b 1 AR and late chronotropic effects to b 2 AR. 6 Our genetic models indicate that PDE5 inhibition counteracts b-adrenergic response mainly through b 2 AR pathways and that PDE2 hydrolyses this subtype-specific cAMP pool, reinforcing the knowledge of the compartmentalization of b 2 AR signalling. The negligible effect of pertussis toxin excludes any major role mediated by coupling of b 2 AR to Gi and therefore related to a reduced cAMP synthesis.
Limitations and perspectives
One limitation of this study is that we could not directly test the impact of PDE5 on b-adrenergic response because PDE5 conditional knockout mice are not available. Another limitation is that we could not entirely dissect weather PDE5 inhibition effects are directly related to PDE2 activation and/or to PKG activation, because of the profound effect that DT2 had on basal rate. However, our findings are consistent with Fischmeister's studies demonstrating that PKG exerts a feedback loop on both the soluble and particulate pools of cGMP, in an opposite manner. 50 Finally, although we showed that neonatal cardiomyocytes express the same molecular machinery as adult cells, they do show some functional differences from mature cardiomyocytes. Despite this, our data on contraction rate obtained from the SAN of adult mice support the physiological relevance of these findings. Interestingly, a recent study found a similar PKG-independent/PDE2-mediated crosstalk between cAMP and cGMP in neurons stimulated with dopamine, suggesting that this could be a more general mechanism conserved among different cell types. 60 Compared with in-vivo studies, our ex-vivo model enabled investigation of the chronotropic response to catecholamines without interference by autonomic nervous or cardiac conduction tissue, which would not be possible with adult cardiomyocytes. Furthermore, most previous studies focused on inotropism, and to our knowledge ours is the first report on contraction rate modulation in cardiac syncytia. Finally, we located this sildenafil-modulated cross-talk between cyclic nucleotides in the b 2 -subtype of the adrenergic receptor, confirming the existence of distinct sub-compartments in cyclic nucleotides that respond differently to pharmacological modulation.
In summary, our data on chronotropy are consistent with other studies, mainly focusing on hypertrophy and inotropy, showing that there are several pathways targeted by sildenafil, with potentially different pharmacological implications. 42, 61, 62 Since the benefits of sildenafil use is still debated, 22,63 -65 the potential of the beta-attenuation properties of PDE5 inhibition deserves further clinical evaluation.
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